i3 Verticals Announces Earnings Release and Conference Call Date for Second Quarter of Fiscal 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)--i3 Verticals, Inc. (Nasdaq: IIIV) ('i3 Verticals' or the 'Company'), announced today that it will release its financial results for the second quarter ended March 31, 2025, on Thursday, May 8, 2025, after the Nasdaq market close.
The Company will also host a conference call on Friday, May 9, 2025, at 8:30 a.m. ET to discuss financial results and operations. To listen to the call live via telephone, participants should dial (844) 887-9399 approximately 10 minutes prior to the start of the call. A telephonic replay will be available from 11:30 a.m. ET on May 9, 2025, through May 16, 2025, by dialing (877) 344-7529 and entering Confirmation Code 5899364.
To listen to the call live via webcast, participants should visit the 'Investors' section of the Company's website, www.i3verticals.com, and go to the 'Events & Presentations' page approximately 10 minutes prior to the start of the call. The online replay will be available on this page of the Company's website beginning shortly after the conclusion of the call and will remain available for 30 days.
About i3 Verticals
The Company seamlessly delivers integrated software and services to customers in strategic vertical markets. Building on its sophisticated and diverse platform of software and services solutions, the Company creates and acquires software products to serve the specific needs of public and private organizations in its Public Sector and Healthcare verticals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Finnish Fiberwood Secures €3.1M EU Grant to Scale Carbon-Storing Building Materials
JÄRVENPÄÄ, Finland--(BUSINESS WIRE)--Finnish deep tech startup Fiberwood Ltd has secured €3.1 million in funding from the EU LIFE Programme to reduce buildings' carbon footprints. The company will use the grant to scale up its sustainable insulation solutions made from wood industry side streams and accelerate its entry into broader European markets. 'We believe forests deserve smarter use,' says CEO Tage Johansson. 'We're turning side streams into something more valuable." Share By refining underutilised materials such as mechanical wood residues and recycled wood into high-performance components, Fiberwood adds value to the forest industry and promotes circular use of timber. Its plastic-free, recyclable fibre boards can replace fossil-based insulation in construction and support the EU's transition to low-emission building practices. Tackling a Global Challenge in Construction The construction sector accounts for 42% of global greenhouse gas emissions. In the EU, most insulation materials are still fossil-based, and over 98% end up in landfills or the environment. While demand for greener alternatives is rising, many bio-based options fall short of technical requirements. Fiberwood aims to bridge that gap. Founded in 2019, the company has developed a patented technology to produce recyclable and compostable boards with thermal performance, structural durability, fire safety, moisture resistance, and material longevity. This rare combination opens new possibilities for sustainable design. 'We believe forests deserve smarter use,' says CEO Tage Johansson. 'We're turning side streams into high-performance materials that meet real construction needs while reducing environmental impact.' Backed by the EU to Accelerate Market Readiness Fiberwood is building a demo production line in Järvenpää, southern Finland, to enable deliveries for customers' pilot projects. The €3.1M EU LIFE grant supports production optimisation, new side-stream validation, and final performance testing, resulting in a blueprint for Fiberwood's first industrial-scale factory. The company's B2B customers include leading building materials companies in Nordic and European markets. They will integrate the fibre components into their existing products and sell them under their own brands. 'This is a turning point,' Johansson says. 'Our material allows customers to make a sustainable leap without changing how they design or sell their products, giving them a competitive edge with minimal disruption.' Before securing LIFE funding, Fiberwood had raised €10.7 million from investors such as Metsä Spring, Stephen Industries, and public innovation funds. The company is preparing for international growth and seeking partners across the European construction value chain. About Fiberwood Fiberwood is a Finnish deep tech company refining wood industry side streams into sustainable, high-performance building and packaging materials. Its customised fibre components reduce buildings' carbon footprints and support the shift to fossil-free construction. Founded in 2019, Fiberwood serves B2B customers across the Nordic and European building materials sector and is ramping up its first demo production line for pilot projects. Funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.
Business Insider
an hour ago
- Business Insider
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025 To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Business Insider
an hour ago
- Business Insider
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the 'Company'), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. At the effective time of the reverse split, every eight issued and outstanding shares of the Company's common stock will automatically be combined into one issued and outstanding share of the Company's common stock without any change in the par value per share. Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. The reverse stock split will not affect the absolute number of the Company's authorized shares of common stock, which will remain at 500,000,000, but the total number of authorized shares of the Company's common stock available for future issuance will increase. In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding pre-funded warrants and stock options, and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 132.3 million to approximately 16.5 million. RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'will' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, pre-funded warrant holders and option holders, the potential impact of the reverse stock split on the bid price of the Company's common stock, the expected number of shares of common stock to be issued and outstanding following the reverse stock split, and other statements that are not historical fact. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
